Curriculum Vitae PERSONAL INFORMATION Martin Bauer WORK EXPERIENCE December 2004-January 2005 Research associate Medical University of Vienna, Department of Clinical Pharmacology (Austria) Phase I and II studies Pharmacokinetics PET/MR Imaging studies Assessing target tissue penetration with Positron Emission Tomography and Microdialysis DDIs July 2017- Present Senior Consultant Medical University of Vienna, Department of Psychiatry and Psychotherapy (Austria) Outpatients clinic, psychiatric intermediate care unit, emergency psychiatry, memory clinic, Phase II-IV studies March 2011- Present Registered Consultant in Clinical Pharmacology Medical University of Vienna/Vienna General Hospital (Austria) Clinacal pharmacology outpatient clinics, DDIs, pharmacokinetics, microdialysis, PET/MR imaging of ABC transporters, Phase I-II studies March 2014- Present Registered Consultant in Psychiatry Medical University of Vienna/Vienna General Hospital (Austria) General psychiatry, Schizophrenia, affective disorders, dementia, child and adolescent psychiatry March 2015- Present Ethics committee member Medical University of Vienna/Vienna General Hospital (Austria) Reviewing projects, discussion July 2016- Present Associate Professor of Clinical Pharmacology Medical University of Vienna/Vienna General Hospital (Austria) Teaching, provide training, Senior Principal Investigator Clinical Research Phase I-II studies, DDIs, pharmacokinetics, bioequivalence, microdialysis, PET/MR imaging of ABC transporters EDUCATION AND TRAINING January 2005-March 2014 Clinical training (Psychiatry, Clinical Pharmacology) Medical University of Vienna/Vienna General Hospital (Austria) August 2006-August 2006 EudraVigilance User Training Certificate EMEA (United Kingdom) Pharmacovigilance January 2015-October 2015 Research Fellow University of Manchester (United Kingdom) Neuroinflammation and Neurooncology. Preclinical and clinical imaging. ADDITIONAL INFORMATION Expertise Clinical Pharmacology, Target Tissue Pharmacokinetics, Pharmacokinetics, 12/02/2021 European Medicines Agency Page 1/6 Psychiatry, Schizophrenia, Depression, Drug Development, Phase I, Phase II, Blood-Brain Barrier, Drug Transporters, Positron Emission Tomography, Microdosing. Train patient rappresentatives Publications Peer-Reviewed Original Articles 2005-2020 Cumulative impact factor: 277 (125 as first, senior or corresponding author) (* corresponding author, # contributed equally, IF= impact factor) 1.A Weidenauer#, M Bauer#, U Sauerzopf, L Bartova, N Lukas, S Pfaff, C Philippe, N Berroterán-Infante, V Pichler, B Meyer, U Rabl, P Sezen, P Cumming, T Stimpfl, H Sitte, R Lanzenberger, N Mossaheb, A Zimprich, P Rusjan, G Dorffner, M Mitterhauser, M Hacker, L Pezawas, S Kasper, W Wadsak, N Praschak-Rieder, M Willeit. On the relationship of first-episode psychosis to the am-phetamine-sensitized state: A dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry (2020) 10:2 https://doi.org/10.1038/s41398-019-0681-5 IF 2017 5.182 2.N Hommer, M Kallab, S Szegedi, S Puchner, K Stjepanek, M Bauer, R Werkmeister, L Schmetterer, M Abensperg-Traun, G Garhofer, D Schmidl. The effect of orally administered dronabinol on optic nerve head blood flow in healthy subjects- a randomized clinical trial. Clin Pharmacol Ther (2020) 108(1):155-161. doi: 10.1002/cpt.1797 IF 2017 6.544 3.I Hernández Lozano, M Bauer, B Wulkersdorfer, A Traxl, C Philippe, M Weber, S Häusler, B Stieger, U Jäger, S Mairinger, T Wanek, M Hacker, M Zeitlinger, O Langer. Measurement of hepatic ABCB1 and ABCG2 transport activity with [11C]tariquidar and PET in humans and mice. Mol Pharmaceut (2019) [accepted on 02.12.2019] IF 2017 4.556 4.B Wulkersdorfer, M Bauer, R Karch, H Stefanits, C Philippe, M Weber, T Czech, M-C Menet, X Declèves, JA Hainfellner, M Preusser, M Hacker, M Zeitlinger, M Müller, O Langer. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast enhancing brain tumors with positron emission tomography. EJNMMI Research (2019) [accepted on 01.12.2019] IF 2017 2.630 5.V Zoufal, S Mairinger, M Brackhan, M Krohn, T Filip, M Sauberer, J Stanek, T Wanek, N Tournier, M Bauer, J Pahnke, O Langer. Imaging P-glycoprotein Induction at the Blood-Brain Barrier of a Beta-Amyloidosis Mouse Model with 11C-Metoclopramide PET. J Nucl Med (2019) [accepted on 18.10.2019] IF 2017 7.439 6.LKS Sundar, O Muzik, L Rischka, A Hahn, R Lanzenberger, M Hienert, E-M Klebermass, M Bauer, I Rausch, E Pataraia, T Traub-Weidinger and T Beyer. The promise of fully-integrated PET/MR imaging: Non-invasive clinical quantification of cerebral glucose metabolism. J Nucl Med (2019) [accepted on 15.07.2019] IF 2017 7.439 7.V Touzeau, M Skoll, P Tajpara, P Kienzl, A Wesinger, S Saluzzo, M Bauer, MC Aichelburg, C Bangert, W Bauer, G Stingl, A Rieger, K Grabmeier-Pfistershammer, C Schuster. Preva-lence of skin-specific autoantibodies in HIV-infected patients and uninfected controls. Acta Dermato-Venereologica (2019) 99(11):978-983. doi: 10.2340/00015555-3251 IF 2017 3.000 8.I Hernández Lozano, R Karch, M Bauer, M Blaickner, A Matsuda, B Wulkersdorfer, M Ha-cker, M Zeitlinger, O Langer. Towards improved pharmacokinetic models for the analysis of transporter-mediated hepatic disposition of drug molecules with positron emission tomogra-phy. AAPS Journal (2019) 21(4):61. doi: 10.1208/s12248-019-0323-0 IF 2017 3.804 9.M Bauer, N Tournier, O Langer. Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to CNS drugs. Clin Pharmacol Ther (2019) 105(5):1061-1064. doi: 10.1002/cpt.1402. IF 2017 6.544 10.A Traxl, S Mairinger, T Filip, M Sauberer, J Stanek, S Poschner, W Jäger, V Zoufal, G Novarino, N Tournier, M Bauer, T Wanek, O Langer. Inhibition of ABCB1 and ABCG2 at the mouse blood-brain barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. Mol Pharmaceut (2019) 16 (3),12821293 doi: 12/02/2021 European Medicines Agency Page 2/6 10.1021/acs.molpharmaceut.8b01217 IF 2017 4.556 11.N Tournier#, M Bauer#*, V Pichler, L Nics, E-M Klebermass, K Bamminger, S Poschner, P Matzneller, M Weber, F Caillé, S Auvity, S Marie, W Jäger, W Wadsak, Marcus Hacker, M Zeitlinger, O Langer. Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Sub-strate 11C-Metoclopramide Assessed with PET Imaging in Humans. J Nucl Med (2019) 60(7):985-991. doi: 10.2967/jnumed.118.219972 IF 2017 7.439 12.M Bauer, R Karch, B Wulkersdorfer, C Philippe, L Nics, E-M Klebermass, M Weber, S Poschner, H Haslacher, W Jäger, N Tournier, W Wadsak, M Hacker, M Zeitlinger, O Langer. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. J Nucl Med. (2019) 60:486-491. doi: 10.2967/jnumed.118.216432 IF 2017 7.439 13.M Bauer, A Traxl, A Matsuda, R Karch, C Philippe, L Nics, EM Klebermass, B Wulkersdorfer, M Weber, S Poschner, N Tournier, W Jäger, W Wadsak, M Hacker, T Wanek, M Zeitlinger, O Langer. Effect of rifampicin on the distribution of [11C]erlotinib to the liver, a translational PET study in humans and in mice. Mol Pharm (2018) 1;15(10):4589-4598. doi: 10.1021/acs.molpharmaceut.8b00588. IF 2017 4.556 14.D Amor, S Goutal, S Marie, F Caillé, M Bauer, O Langer, S Auvity, N Tournier. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib as-sessed with PET imaging in rats. EJNMMI Research (2018) 16;8(1):81 IF 2017 2.630 15.S Auvity, F Caillé, S Marie, C Wimberley, M Bauer, O Langer, I Buvat, S Goutal, N Tournier. P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates. J Nucl Med (2018). 59(10):1609-1615. doi: 10.2967/jnumed.118.210104. IF 2017 7.439 16.C Schuster, FJ Mayer, C Wohlfahrt, R Marculescu, M Skoll, R Strassl, N Pavo, T Popow-Kraupp, M Hülsmann, M Bauer, MC Aichelburg, A Rieger, G Goliasch. Acute HIV infection results in sub-clinical inflammatory cardiomyopathy. J Infect Dis (2018) 2;218(3):466-470 doi: 10.1093/infdis/jiy183 IF 2017 5.186 17.P Matzneller, M Kussmann, S Eberl, A Maier-Salamon, W Jäger, M Bauer, O Langer, M Zeitlinger, W Poeppl. Pharmacokinetics of the P-gp inhibitor tariquidar in rats after intravenous, oral and intraperitoneal administration. Eur J Drug Metab Pharmacokinet (2018) 43(5):599-606 doi: 10.1007/s13318-018-0474-x. IF 2017 1.362 18.A Chaney, M Bauer#, D Bochicchio#, A Semigova, M Kassiou, KE Davies, SR Williams, H Boutin Longitudinal investigation of neuroinflammation and metabolite profiles in the APPswe×PS1e9 transgenic mouse model of Alzheimers disease. J Neurochem (2018) 144(3):318-335. doi: 10.1111/jnc.14251 IF 2017 4.609 19.M Bauer, A Matsuda, B Wulkersdorfer, C Philippe, A Traxl, C Özvegy-Laczka, J Stanek, L Nics, EM Klebermass, S Poschner, W Jäger, I Patik, E Bakos, G Szakács, W Wadsak, M Hacker, M Zeitlinger, O Langer. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Clin Pharmacol Ther (2018) 104(1):139-147. doi: 10.1002/cpt.888 IF 2017 6.544 20.ML Lassen, O Mutzik, T Beyer, M Hacker, CN Ladefoged, J Cal Gonzalez, W Wadsak, I Rausch, M Zeitlinger, O Langer, M Bauer*. Reproducibility of Quantitative Brain Imaging Using a PET-only and a Combined PET/MR System. Front Neurosci (2017) 11:396 doi: 10.3389/fnins.2017.00396. eCollection 2017. IF 2017 3.877 21.M Bauer, B Wulkersdorfer, R Karch, C Philippe, W Jäger, W Wadsak, M Hacker, M Zeitlin-ger, O Langer. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly versus young subjects. Br J Clin Pharmacol. (2017) 83(9):1991-9 doi: 10.1111/bcp.13301 IF 2017 3.838 22.A Matsuda, R Karch, M Bauer, A Traxl, M Zeitlinger, O Langer.